Compare Annaly Capital Management, Inc. (NLY) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Annaly Capital Management, Inc. vs Novavax Inc — how do they compare? Annaly Capital Management, Inc. trades at $23.3 (market cap $17.44B), while Novavax Inc trades at $7.93 (market cap $1.31B). The key difference: Annaly Capital Management, Inc. is far larger — about 13.3× Novavax Inc's market cap, and Annaly Capital Management, Inc. pays a 12.96% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NLY | NVAX | |
|---|---|---|
Market Cap | $17.44B | $1.31B |
Sector | Financials | Health |
52-Week High | $24.40 | $11.19 |
52-Week Low | $20.21 | $6.22 |
Dividend Yield | 12.96% | — |
Enterprise Value | — | $889.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NLY trades at $23.28, up 1.62% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a low P/E of 5.59 and a high ROE of 20.66%. Recent quarterly earnings have consistently beaten estimates, and the company maintains a significant dividend yield. Analyst consensus is positive, with a $24.50 price target, supported by recent upgrades and institutional buying activity.
The outlook for NLY is favorable, driven by earnings growth and a high dividend yield, but risks include interest rate sensitivity and high leverage. The stock offers value and income appeal, yet investors should weigh the cyclical nature of the mortgage REIT sector against the strong analyst support and recent financial performance.
Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.
The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
